AZN vs NVO
AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | AZN | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $169.73 | $48.19 | |
| Market cap as of 2026-07-23 | $193.7B | $219.8B | |
| P/E as of 2026-07-23 | 24.93 | 11.78 | NVO lower |
| PEG as of 2026-07-23 | 2.64 | 16.16 | AZN lower |
| Net margin as of 2026-07-23 | +17.2% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +81.4% | +81.8% | NVO higher |
| Operating margin as of 2026-07-23 | +23.7% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | +22.3% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | +9.1% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.72 | AZN lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | +8.1% | AZN higher |
| Dividend yield as of 2026-07-23 | +1.9% | +3.7% | NVO higher |
| Beta as of 2026-07-23 | 1.38 | 1.85 | |
| 1-year return as of 2026-07-22 close | +17.0% | -23.8% | AZN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.